Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy

Journal of Clinical Oncology

Volumn 22, Issue 8, 2004, Pages 1454-1459

  Advani, Ranjana ^a   Rosenberg, Saul A ^a   Horning, Sandra J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; INCIDENCE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION FIELD; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT REFUSAL; XEROSTOMIA; ADULT; AGED; FEMALE; LYMPHOCYTOMA; MALE; MIDDLE AGED; MIXED CELL LYMPHOMA; MORTALITY; PATHOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, MIXED-CELL, FOLLICULAR; LYMPHOMA, NON-HODGKIN; LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 2342560524     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.086     Document Type: Article

References (33)

1. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
2. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage - The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112-2135, 1982
3. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984
4. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993 (suppl 5)
5. Glick JH, Barnes JM, Ezdinli EZ, et al: Nodular mixed lymphoma: Results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 58:920-925, 1981
6. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemo immunotherapy. J Clin Oncol 11:644-651, 1993
7. Hoppe RT, Kushlan P, Kaplan HS, et al: The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 58:592-598, 1981
8. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires-Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1110-1117, 1997
9. Ardeshna KM, Smith P, Norton A, et al: British National Lymphoma Investigation: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma-A randomized controlled trial. Lancet 362:516-522, 2003
10. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment. Semin Hematol 25:11-16, 1988 (suppl 2)
11. Engelhard M, Stuschke M: Report on workshop: UICC workshop "Therapy of NHL in early stages," part 1-Follicular lymphoma. Ann Hematol 80:13-15, 2001 (suppl 3)
12. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996
13. Gospodarowicz MK, Bush RS, Brown TC, et al: Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 10:489-497, 1984
14. Pendlebury S, el Awadi M, Ashley S, et al: Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 36:167-171, 1995
15. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al: Clinical stage 1 non-Hodgkin's lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69:1088-1093, 1994
16. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971
17. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma: The International NHL Prognostic Factors Project. N Engl J Med 329:987-994, 1993
18. Kaplan ES, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 53:270-283, 1958
19. Soubeyran P, Eghbali H, Trojani, et al: Is there any place for a wait-and-see policy in stage I 0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol 7:713, 1996
20. Seymour JF, Pro B, Fuller LM, et al: Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I-II Indolent Non-Hodgkin's Lymphoma. J Clin Oncol 21: 2115-2122, 2003
21. Bastion Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997
22. Yuen AR, Kamel OW, Halpern J, et al: Long-term survival after histological transformation of low-grade follicular lymphoma. J Clin Oncol 13:1726-1733, 1995
23. Solal-Celigny P, Bernard J, Roy P: Follicular lymphoma international prognostic project (FLIPP). Ann Oncol 13:18, 2002 (abstr 54)
24. de Vos S, Hofmann WK, Grogan TM, et al: Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 83: 271-285, 2003
25. Bohen SP, Troyanskaya OG, Alter O, et al: Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A 100:1926-1930, 2003
26. Viardot A, Moller P, Hogel J, et al: Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol 20: 4523-4530, 2002
27. Buchonnet G, Jardin F, Jean N, et al: Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: Specific subtypes or same disease? Leukemia 16:1852-1856, 2002
28. Moller MB, Nielsen O, Pedersen NT: Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology 41:322-330, 2002
29. Akasaka T, Lossos IS, Levy R: BCL6 gene translocation in follicular lymphoma: A harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 102:1443-1448, 2003
30. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003
31. Cohen Y, Solal-Celigny P, Polliack A: Rituximab therapy for follicular lymphoma: A comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, retreatment and maintenance. Haematologica 88: 811-823, 2003
32. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
33. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001